CAESAREA, Israel, Jan. 6, 2025
/PRNewswire/ -- IceCure Medical Ltd. (NASDAQ: ICCM)
("IceCure", "IceCure Medical" or the "Company"), developer of
minimally-invasive cryoablation technology that destroys tumors by
freezing as an alternative to surgical tumor removal, today
announced it has received a notification letter from Nasdaq Stock
Market LLC ("Nasdaq") confirming that it has regained compliance
with the minimum bid price requirement set forth in Nasdaq Listing
Rule 5550(a)(2) (the "Rule").
The Nasdaq staff made this determination of compliance with the
Rule after the Company's ordinary shares was at a minimum closing
bid price of $1.00 or more for at
least 10 consecutive business days prior to the date of the notice.
Accordingly, the Company has regained compliance with the Rule and
Nasdaq considers the prior bid price deficiency matter now
closed.
IceCure is now in full compliance with all Nasdaq continued
listing requirements and will continue to be listed and traded on
The Nasdaq Capital Market.
About IceCure Medical
IceCure Medical (NASDAQ: ICCM) develops and markets advanced
liquid-nitrogen-based cryoablation therapy systems for the
treatment of tumors (benign and cancerous) by freezing, with the
primary focus areas being breast, kidney, bone and lung cancer. Its
minimally invasive technology is a safe and effective alternative
to hospital surgical tumor removal that is easily performed in a
relatively short procedure. The Company's flagship
ProSense® system is marketed and sold worldwide for the
indications cleared and approved to date including in the U.S.,
Europe and China.
Forward Looking Statements
This press release contains forward-looking statements within
the meaning of the "safe harbor" provisions of the Private
Securities Litigation Reform Act of 1995 and other Federal
securities laws. Words such as "expects," "anticipates," "intends,"
"plans," "believes," "seeks," "estimates" and similar expressions
or variations of such words are intended to identify
forward-looking statements. For example, IceCure is using forward
looking statements in this press release when it discusses the
continued listing or meeting of the continued listing requirements.
Forward-looking statements are not historical facts, and are based
upon management's current expectations, beliefs and projections,
many of which, by their nature, are inherently uncertain. Such
expectations, beliefs and projections are expressed in good faith.
However, there can be no assurance that management's expectations,
beliefs and projections will be achieved, and actual results may
differ materially from what is expressed in or indicated by the
forward-looking statements. Important factors that could cause
actual results, developments and business decisions to differ
materially from those anticipated in these forward-looking
statements include, among others: the Company's planned level of
revenues and capital expenditures; the Company's available cash and
its ability to obtain additional funding; the Company's ability to
market and sell its products; legal and regulatory developments in
the United States and other
countries; the Company's ability to maintain its relationships with
suppliers, distributors and other partners; the Company's ability
to maintain or protect the validity of its patents and other
intellectual property; the Company's ability to expose and educate
medical professionals about its products; political, economic and
military instability in the Middle
East, specifically in Israel; as well as those factors set forth in
the Risk Factors section of the Company's Annual Report on Form
20-F for the year ended December 31,
2023 filed with the SEC on April 3,
2024, and other documents filed with or furnished to the SEC
which are available on the SEC's website, www.sec.gov. The Company
undertakes no obligation to update these statements for revisions
or changes after the date of this release, except as required by
law.
IR Contact:
Email: investors@icecure-medical.com
Michael Polyviou
Phone: 732-232-6914
Todd Kehrli
Phone: 310-625-4462
Logo:
https://mma.prnewswire.com/media/2319310/IceCure_Medical_Logo.jpg
View original
content:https://www.prnewswire.com/news-releases/icecure-medical-regains-full-nasdaq-compliance-with-nasdaq-minimum-closing-bid-price-rule-302342739.html
SOURCE IceCure Medical